Category: BioTech
The analysis published under this category are as follows.
Friday, April 17, 2015
How to Profit from Australia's Healthiest Biotech Stocks / Companies / BioTech
By: TLSReport
Australia will always be known as a trove of natural resources, but its most precious treasure is the abundance of entrepreneurs who are all too happy to develop the country's intellectual assets. Shane Storey, head of research at Australia-based Wilson HTM Investment Group, observes that as the market value of resource commodities declines, investors are diverting investment capital to healthcare stocks, especially in the medical technology sector. In this interview with The Life Sciences Report, Storey presents three names that don't come close to their long-term fair valuation potential. The upside, he believes, could be quite dramatic.
Friday, April 03, 2015
Fat Loss Pills - How to Profit from America's $20 Billion Waistline War / Companies / BioTech
By: Money_Morning
Ernie Tremblay writes: Weight loss is a $20 billion per year industry. Yet, it seems the more we spend on shedding pounds, the more pounds we have to shed. Today, two-thirds of adults and one-third of children in the U.S. are overweight or obese, and the numbers are climbing.
With a growing market of that magnitude and so much money changing hands, it's no wonder investors' eyes light up when they hear the words "new obesity drug."
Read full article... Read full article...
Wednesday, March 11, 2015
Biotech Stocks Blowoff Beats Even Dot-Com Madness / Companies / BioTech
By: Anthony_Alfidi
Annual health tech fests like the JPMorgan Health Care Conference, Biotech Showcase, and One Med Forum came and went this year in San Francisco. The star performers in this sector no doubt have a lot to brag about. They will also have a lot of explaining to do when the biotech and health care sectors eventually crash.
Read full article... Read full article...
Saturday, February 21, 2015
The Seven Financial Indicators of Highly Successful Biotech Stocks Investing / Companies / BioTech
By: Money_Morning
Ernie Tremblay writes: When evaluating biotech stocks, many key indicators that work for other industries – e.g. price-to-earnings ratio, profit margin, revenue-per-share – often don't apply.
Here's why they don't, and why seven of these critical financial indicators do…
Read full article... Read full article...
Wednesday, December 31, 2014
Will Biotech Stocks Sector Fire on All Cylinders in 2015? / Companies / BioTech
By: TLSReport
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early 2014 before rebounding, essentially following the upward trend that most experts forecast. What is in store for 2015? The Life Sciences Report turned to newsletter writer John McCamant and WBB Securities' Steve Brozak for insight.
Thursday, December 11, 2014
Genetic Cures for Disease: Impossible Biotech Dream Come True? / Companies / BioTech
By: TLSReport
Clinicians like to speak in terms of "managing" disease. That term of art is an admission that, in most cases, they can't cure the serious problems confronting patients. In this interview with The Life Sciences Report, David Nierengarten of Wedbush Securities explores gene therapies that actually correct an inborn mutation in human DNA, creating permanent change, actual cures and better lives for patients. It sounds beyond the reach of medicine . . . and therein lies the opportunity: Investors in gene therapy companies may capture serious returns on risk capital when the cure is attained.
Tuesday, December 02, 2014
Bio-Tech Stock That Will Profit from a New Breakthrough Medical Direction / Companies / BioTech
By: Money_Morning
Ernie Tremblay writes: Modern medicine, for all of its sophisticated drugs, complex gadgets, and amazing surgical procedures, rarely cures anything. It treats. It manages. It postpones the inevitable.
But return a patient to normal, optimal health?
Read full article... Read full article...
Friday, November 21, 2014
Two Biotech Stocks Set to Double on One Powerful Catalyst / Companies / BioTech
By: Money_Morning
William Patalon writes: When I earned my MBA from the Rochester Institute of Technology (RIT) back in the mid-1990s, my focus was finance and investing.
But it was a management professor who clued me in to some of the best ways to "look past the numbers" and understand what really makes a big company tick.
The professor, Janet C. Barnard, retired a few years back and, sadly, passed away in 2012.
Read full article... Read full article...
Friday, October 24, 2014
Natus Medical Justifies Recent Run With Record Q3 Results / Companies / BioTech
By: Submissions
Nicholas Maithya writes: Natus Medical (NASDAQ:BABY) is up more than 125% over the last twelve months and based on recent results, that run seems fully justified with room left for more. The stock closed at $33.51 on Thursday 23, up 2.16% for the day following its impressive results released on the previous day.
Thursday, October 23, 2014
Japan Gives a Hug to the Cell Therapy Biotech Industry / Companies / BioTech
By: TLSReport
Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview with The Life Sciences Report, former regenerative medicine consultant R. Lee Buckler, now a vice president with RepliCel Life Sciences Inc., puts his consultant's hat back on to talk about Japan's hospitable stance on proposed cell therapies. He provides an update on the meaning of the new law and discusses a small cohort of companies poised to reap the advantages.
Wednesday, October 22, 2014
Follow the Baby Boom to Biotech Stock Profits / Companies / BioTech
By: TLSReport
In recent years, entrepreneurial therapists have comprised the fast-growing sector in outpatient physical therapy. But companies like Agility Health are beginning to seize acquisition opportunities and market share in this growing sector. Steven Davidson, CEO of Agility Health Inc., tells The Life Sciences Report how his company is innovating in the physical therapy space, improving patient care and clients' bottom lines through its management expertise and proprietary software, AgileRPM. With baby boomers aging and the Affordable Care Act increasing access to services, physical therapy just might be the safe haven sector to shield your portfolio from macroeconomic uncertainty.
Friday, September 12, 2014
Apple’s Smartwatch May put Biotech on Silicon Valley Time / Companies / BioTech
By: John_Mauldin
By Patrick Cox
Tech sites are buzzing right now about the new Apple smartwatch and iPhone. Having been a part of or close to the tech industry for a long time, the excitement that builds over new products doesn’t normally move me much. This time, though, it’s a little different because of reports that the phone and watch will be integrated to support healthcare apps.
Read full article... Read full article...
Saturday, August 23, 2014
Oxaloacetate Feeds and GROWS Brain Cells - Alzheimers Cure? / Companies / BioTech
By: John_Mauldin
By Patrick Cox
Oxford Paper Shows Oxaloacetate Feeds and Grows Brain Cells
The headline above is good news for those of us who want to proactively protect our health and extend our lives. I remain pretty cynical about the vast majority of supplements that claim life-extension benefits, but this compound is one of the rare exceptions. Before describing this important paper, published by in the Oxford journal Human Molecular Genetics, let me explain a bit about oxaloacetate, which John Mauldin and I both take several times a day.
Read full article... Read full article...
Thursday, August 07, 2014
New Growth Ideas for Biotech Stock Investors / Companies / BioTech
By: TLSReport
Medical technology is intimately linked to regenerative medicine. You could say these industries have a thunder-and-lightning relationship—you can't have one without the other. Mark Landy, director of research for medical technology and regenerative medicine at Summer Street Research Partners, has staked out the intertwined sectors as his universe of coverage. In this interview with The Life Sciences Report, Landy discusses three companies with very distinct capabilities that could bring extraordinary rewards to investors who understand the value propositions.
Friday, August 01, 2014
Turning a Clinical Eye on Biotech Stocks with High Potential Investor Reward / Companies / BioTech
By: TLSReport
A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand, recommends that investors willing to diversify their holdings and take on informed risk hold a short list of companies with huge potential. James, a senior analyst and managing director at Brinson Patrick Securities, is a neurosurgeon by training, and examines new platforms and proposed therapies with a clinician's eye. In this interview with The Life Sciences Report, James turns that eye on three names with dramatic, paradigm-changing technology platforms that could energize portfolios.
Wednesday, July 02, 2014
The BioScience Stocks Profit Outlook for the Rest of 2014 / Companies / BioTech
By: Money_Morning
Ernie Tremblay writes: With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second half of 2014. There are huge opportunities in several subsectors of the bioscience market in particular.
That said, some bioscience analysts are saying there's a bubble. And it's scaring a lot of bioscience investors out of great positions in the market.
That's why last week I shared my complete bioscience market outlook for the rest of 2014 with my paid members - to help them see the real market story.
Read full article... Read full article...
Monday, June 30, 2014
How to Tap Big Profits in That "Other" Bioscience Niche / Companies / BioTech
By: Money_Morning
Ernie Tremblay writes: At first glance, it may seem like bioscience investing is so complicated and risky that it's hardly worth your time and money to invest, at least if you don't have someone knowledgeable to guide you.
And it's true. Putting your money behind new, experimental drugs, without some guidance, is a crapshoot.
But there's an approach to making profits from this sector that doesn't rely on breakthrough discoveries, expensive drug trials, or constant cash infusions through dilutive public offerings to fuel its engine.
Read full article... Read full article...
Wednesday, June 18, 2014
Not Even Washington's Meddling Could Stop Biotech’s Biggest Comeback / Companies / BioTech
By: Money_Morning
Michael A. Robinson writes: Late last month, I told you that biotech is one of the best ways to profit from the tech rebound. In fact, it was my “No Doz Opportunity No. 1.”
Somewhat ironically, a rollover in the biotech market was one of the proximate causes of the overall selloff in tech earlier this year.
And now I’m recommending that you invest in the company that purportedly “caused” the biotech market to roll over in the first place.
Read full article... Read full article...
Tuesday, June 10, 2014
Profit From the "Scariest Event" in Bioscience / Companies / BioTech
By: Money_Morning
Ernie Tremblay writes: In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs-down for an experimental drug as it makes its way through the regulatory process.
Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.
Perhaps the least understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.
Read full article... Read full article...
Saturday, May 24, 2014
Healing the Blind… and Boosting Your Stocks Portfolio / Companies / BioTech
By: Casey_Research
By Chris Wood, Senior Analyst
Vision is one of the most important elements of our life, if not the most important one. A 2010 survey by Surge Research found that 60% of Americans are more afraid of blindness than of heart disease, the primary killer of both men and women in the United States.
Read full article... Read full article...